> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # CureVac - URL: https://www.whiteroseintelligence.com/curevac/ - Published: 1999-01-02T14:46:00.000Z - Updated: 2025-05-12T21:07:21.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization **CureVac N.V.** is a German biopharmaceutical company based in Tübingen, Germany. ## History In April 2016, CureVac entered a development and option agreement with Canadian biotechnology company [Acuitas Therapeutics](https://www.whiteroseintelligence.com/Acuitas-Therapeutics) to jointly develop a product incorporating Acuitas' lipid nanoparticle (LNP) technology with CureVac's mRNA materials.[\[1\]](#fn1)[\[2\]](#fn2) The encapsulated mRNA product described under the agreement was commissioned for use in in vitro and animal testing for pre-clinical trials of a vaccine candidate. CureVac entered into an agreement with [Arcturus Therapeutics](https://www.whiteroseintelligence.com/Arcturus-Therapeutics) in January 2018, gaining access to Arcturus's LNP formulation technology for use in CureVac's mRNA platform.[\[3\]](#fn3)[\[4\]](#fn4) ### COVID-19 CureVac partnered with Acuitas Therapeutics and Imperial College London for their [COVID-19 vaccine](https://www.whiteroseintelligence.com/COVID-19-vaccine) trials.[\[5\]](#fn5)[\[6\]](#fn6) CureVac received up to USD $15.3 million for the development of its COVID-19 vaccine candidate, and up to USD $34 million for its Lassa fever vaccine.[\[7\]](#fn7) ## Organization CureVac is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[\[8\]](#fn8) | Name | Position | Notes | | ----------------------- | -------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | | Ingmar Hoerr | Co-Founder and Former Chief Executive Officer[\[9\]](#fn9) | \- | | Franz-Werner Haas | Chief Executive Officer (former)[\[10\]](#fn10) | Sygnis Pharma, LION Bioscience, Sirona Dental Systems | | Stefan Mueller | Vice President Preclinical[\[11\]](#fn11) | Sandoz, Merck Serono, [Merck](https://www.whiteroseintelligence.com/Merck), Knoll | | Lidia Oostvogels | Vice President Area Head Infectious Diseases (former)[\[12\]](#fn12) | Minervax, GlaxoSmithKline (GSK), [Boehringer Ingelheim](https://www.whiteroseintelligence.com/Boehringer-Ingelheim) | | Lívia Palmerston Mendes | Senior Scientist (former)[\[13\]](#fn13) | [NanoVation Therapeutics](https://www.whiteroseintelligence.com/NanoVation-Therapeutics) | | Ralf Clemens | Scientific Advisory Board Chair[\[9:1\]](#fn9) | GlaxoSmithKline (GSK), Novartis, Takeda Pharmaceuticals, [Bill & Melinda Gates Foundation](https://www.whiteroseintelligence.com/Bill-Melinda-Gates-Foundation), Africa Research Excellence Fund (AREF) | | Carol J. Baker | Scientific Advisory Board member[\[9:2\]](#fn9) | Baylor College of Medicine (BCM), [Advisory Committee on Immunization Practices](https://www.whiteroseintelligence.com/Advisory-Committee-on-Immunization-Practices) (ACIP), Infectious Diseases Society of America (IDSA), National Foundation for Infectious Diseases (NFID) | | Nina Bhardwaj | Scientific Advisory Board member[\[9:3\]](#fn9) | Icahn School of Medicine at Mount Sinai, American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), *Cancer Immunology Research* | | Michel de Wilde | Scientific Advisory Board member[\[9:4\]](#fn9) | [COVID-19 Joint Biomanufacturing Subcommittee](https://www.whiteroseintelligence.com/COVID-19-Joint-Biomanufacturing-Subcommittee), [Coalition for Epidemic Preparedness Innovations](https://www.whiteroseintelligence.com/Coalition-for-Epidemic-Preparedness-Innovations) (CEPI), [COVID-19 Vaccine Task Force](https://www.whiteroseintelligence.com/COVID-19-Vaccine-Task-Force) | | Karim Fizazi | Scientific Advisory Board member[\[9:5\]](#fn9) | Institut Gustave Roussy, *European Journal of Cancer* | | Dirk Jäger | Scientific Advisory Board member[\[9:6\]](#fn9) | University Hospital Heidelberg, German Cancer Research Center (DKFZ) | | Christopher Karp | Scientific Advisory Board member[\[9:7\]](#fn9) | [Bill & Melinda Gates Foundation](https://www.whiteroseintelligence.com/Bill-Melinda-Gates-Foundation) | | Michael P. Manns | Scientific Advisory Board member[\[9:8\]](#fn9) | Hannover Medical School (MHH) | | Stanley Plotkin | Scientific Advisory Board member[\[9:9\]](#fn9) | Wistar Institute, University of Pennsylvania, [Johns Hopkins University](https://www.whiteroseintelligence.com/Johns-Hopkins-University) | | Jean-Paul Prieels | Scientific Advisory Board member[\[9:10\]](#fn9) | DNAlytics, Vaximm, GlaxoSmithKline (GSK) | | Hans-Georg Rammensee | Scientific Advisory Board member[\[9:11\]](#fn9) | University of Tübingen | | George Siber | Scientific Advisory Board member[\[9:12\]](#fn9) | ClearPath Vaccines Company (CVC), Wyeth, MassBiologics, [COVAXX](https://www.whiteroseintelligence.com/COVAXX) | | Daniel Speiser | Scientific Advisory Board member[\[9:13\]](#fn9) | Ludwig Cancer Research | | Xiao-Ning Xu | Scientific Advisory Board member[\[9:14\]](#fn9) | Imperial College London, Novartis Vaccines & Diagnostics | | Fred Zepp | Scientific Advisory Board member[\[9:15\]](#fn9) | University Medical Center Mainz, German Society of Pediatrics and Adolescent Medicine (DGKJ), Standing Committee on Vaccination at the Robert Koch Institute (STIKO) | | Gerd Zettlmeissl | Scientific Advisory Board member[\[9:16\]](#fn9) | Hilleman Laboratories, [Aeras Global TB Vaccine Foundation](https://www.whiteroseintelligence.com/Aeras-Global-TB-Vaccine-Foundation), Chiron Behring, Intercell | ### Investors CureVac's investors include: - [Bill & Melinda Gates Foundation Strategic Investment Fund](https://www.whiteroseintelligence.com/Bill-Melinda-Gates-Foundation-Strategic-Investment-Fund) (SIF)[\[14\]](#fn14)[\[15\]](#fn15) ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=pharmaceutical%5Fcompanies:curevac) - [LinkedIn](https://www.linkedin.com/company/curevac/) - [Website](https://www.curevac.com/) - [Wikipedia](https://en.wikipedia.org/wiki/CureVac) --- 1. *Development and Option Agreement between CureVac AG and Acuitas Therapeutics Inc.* (2016, April 29). Securities and Exchange Commission. [↩︎](#fnref1) 2. Plieth, J., & Elmhirst, E. (2020, July 27). *Curevac muddies the Moderna/Arbutus waters further*. Evaluate Vantage. [↩︎](#fnref2) 3. Shores, D., Haversack, D., & Storaska, A. J. (2021, April 11). *The mRNA IP and Competitive Landscape Through One Year of the COVID-19 Pandemic – Part I.* IPWatchdog. [↩︎](#fnref3) 4. *Exhibit 4.12 - Development and Option Agreement by and between CureVac AG and Arcturus Therapeutics Inc.* (2018, January 1). Securities and Exchange Commission. [↩︎](#fnref4) 5. Bianchini, E. (2020, November 10). *Acuitas Therapeutics: The Canadian technology that the Pfizer and BioNTech COVID-19 vaccine “can’t work without.”* Yahoo News. [↩︎](#fnref5) 6. Lowe, D. (2021, June 17). *CureVac Comes Up Short.* Science. [↩︎](#fnref6) 7. *Our portfolio.* CEPI. Retrieved October 21, 2022, from [↩︎](#fnref7) 8. *Membership*. European Federation of Pharmaceutical Industries and Association. Retrieved July 1, 2022, from [↩︎](#fnref8) 9. Mielach, A., & Hunter, R. (2016, March 30). *CureVac Appoints Leading Experts to its Scientific Advisory Board.* CureVac. [↩︎](#fnref9) [↩︎](#fnref9:1) [↩︎](#fnref9:2) [↩︎](#fnref9:3) [↩︎](#fnref9:4) [↩︎](#fnref9:5) [↩︎](#fnref9:6) [↩︎](#fnref9:7) [↩︎](#fnref9:8) [↩︎](#fnref9:9) [↩︎](#fnref9:10) [↩︎](#fnref9:11) [↩︎](#fnref9:12) [↩︎](#fnref9:13) [↩︎](#fnref9:14) [↩︎](#fnref9:15) [↩︎](#fnref9:16) 10. Schüller, T., & Fakih, S. (2020, August 4). *CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer.* CureVac. [↩︎](#fnref10) 11. Schüller, T. (2019, February 3). *CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical.* CureVac. [↩︎](#fnref11) 12. *Lidia Oostvogels.* LinkedIn. Retrieved April 25, 2025, from [↩︎](#fnref12) 13. *Lívia Palmerston Mendes.* LinkedIn. Retrieved April 25, 2025, from [↩︎](#fnref13) 14. *Portfolio - Page 2.* Bill & Melinda Gates Foundation Strategic Innovation Fund. Retrieved September 27, 2023, from [↩︎](#fnref14) 15. Schwab, T. (2020, August 21). *Journalism’s Gates keepers.* Columbia Journalism Review. [↩︎](#fnref15)